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Abstract
Background: BORIS/CTCFL is a paralogue of CTCF, the major epigenetic regulator of vertebrate genomes. BORIS is normally
expressed only in germ cells but is aberrantly activated in numerous cancers. While recent studies demonstrated that BORIS
is a transcriptional activator of testis-specific genes, little is generally known about its biological and molecular functions.
Methodology/Principal Findings: Here we show that BORIS is expressed as 23 isoforms in germline and cancer cells. The
isoforms are comprised of alternative N- and C-termini combined with varying numbers of zinc fingers (ZF) in the DNA
binding domain. The patterns of BORIS isoform expression are distinct in germ and cancer cells. Isoform expression is
activated by downregulation of CTCF, upregulated by reduction in CpG methylation caused by inactivation of DNMT1 or
DNMT3b, and repressed by activation of p53. Studies of ectopically expressed isoforms showed that all are translated and
localized to the nucleus. Using the testis-specific cerebroside sulfotransferase (CST) promoter and the IGF2/H19 imprinting
control region (ICR), it was shown that binding of BORIS isoforms to DNA targets in vitro is methylation-sensitive and
depends on the number and specific composition of ZF. The ability to bind target DNA and the presence of a specific long
amino terminus (N258) in different isoforms are necessary and sufficient to activate CST transcription. Comparative
sequence analyses revealed an evolutionary burst in mammals with strong conservation of BORIS isoproteins among
primates.
Conclusions: The extensive repertoire of spliced BORIS variants in humans that confer distinct DNA binding and
transcriptional activation properties, and their differential patterns of expression among germ cells and neoplastic cells
suggest that the gene is involved in a range of functionally important aspects of both normal gametogenesis and cancer
development. In addition, a burst in isoform diversification may be evolutionarily tied to unique aspects of primate
speciation.
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Introduction
BORIS (Brother Of the Regulator of Imprinted Sites) is a
paralog of the multifunctional CTCF gene, which is involved in
reading epigenetic marks, transcriptional gene activation and
repression, X-chromosome inactivation, chromatin loop formation
through dimerization and in global three-dimensional genome
organization [1,2,3,4,5]. While the two proteins share a central 11
zinc finger (ZF) DNA binding domain, they have distinct amino-
and carboxy-termini [2,6]. In normal tissues, the two paralogous
genes show mutually exclusive expression patterns: BORIS mRNA
is abundant in male germ cells, particularly in primary
spermatocytes and round spermatids, where CTCF, which is
expressed ubiquitously in somatic cells, is repressed [2]. BORIS
acts as transcriptional activator of multiple testis-specific target
genes during spermatogenesis, while CTCF suppresses the same
targets in somatic cells [7,8,9]. In germ cells, BORIS was
suggested to be involved in the resetting of imprinting at the
Igf2/H19 imprinting control region (ICR) [10]. In contrast, CTCF
is the known reader and protector of Igf2/H19 imprinting marks in
somatic cells [11,12,13,14,15]. The segregation of BORIS and
CTCF expression in different cell types in mammals is tightly
controlled. Normally, CTCF, p53, and CpG methylation suppress
BORIS transcription in somatic cells, effectively restricting its
expression to testicular germ cells [8,16], where the absence of
CTCF [2] and several waves of genome-wide demethylation
create the conditions for BORIS activation.
BORIS is aberrantly activated in many types of cancer cells, its
expression coinciding with the loss of CpG methylation, the first
epigenetic change identified in cancer cells [2,6,17]. Aberrant
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13872expression of BORIS in cancer cells likely results in a competition
between BORIS and CTCF proteins for binding to CTCF DNA
binding target sites (CTSes). BORIS can interfere with CTCF
functions in cancer cells not just by virtue of having the identical
ZF binding domain and overlapping DNA binding specificity, but
also due to its distinct amino- and carboxy-termini that likely
confer a discrete set of molecular functions [2]. Indeed, both
CTCF and BORIS bind the MAGE A1 promoter, but with
opposing results: while CTCF acts as a transcriptional repressor,
BORIS functions as an activator [8]. A recent study also
demonstrated that BORIS and CTCF perform different tran-
scriptional functions upon binding to the promoter of mouse testis-
specific CST splice variant [9]. In conclusion, although molecular
functions of BORIS in cancer remain to be studied in depth,
aberrant co-expression of CTCF and BORIS is one of the gene
expression signatures characteristic of many cancers [6].
Previous studies showed that the evolutionary emergence of
BORIS in amniotes occurred before the divergence of reptiles and
mammals and could be attributed to an initial duplication of the
entire CTCF sequence [18]. While BORIS is widely expressed in
reptiles and monotremes, expression was shown to be gonad-
specific in marsupials and eutherians, indicating that BORIS
became functionally specialized during mammalian evolution in
concert with the evolution of genomic imprinting [18]. While
CTCF is highly conserved from drosophila to humans [18,19,20],
BORIS coding and noncoding sequences are evolutionarily plastic
[18]. Indeed, a comparison of the amino- and carboxy-termini of
human BORIS with orthologs in other species reveals relatively low
similarity, 32.3% and 23.7%, respectively, whereas the corre-
sponding similarity of human CTCF with other orthologs is 90.1%
and 80.7%, respectively. Nonetheless, the BORIS ZF region has
80.4% identity to its orthologs, similar to the 99.5% conservation
for CTCF ZFs [18]. The rapid evolution of BORIS is not limited to
protein coding sequences. Remarkably, the structure of the locus
as a whole is notably different even between mice and humans,
which may suggest a specialized set of functions and/or splicing
isoforms. The human BORIS gene spans over 29 kb at 20q13 and
is comprised of 11 exons, 10 of which are coding [2]. This may
permit the generation of a number of different isoforms by
alternative splicing. Evolutionarily, alternative splicing is the most
widely used mechanism for increasing the coding capacity of
mRNA transcripts to allow generation of different protein isoforms
with distinct activities.
The first evidence for alternative BORIS transcripts came from
the recent demonstration that human BORIS is expressed from at
least three alternative promoters utilizing five distinct 59 UTRs
[16]. In the present study, we characterized 23 BORIS splice
variants with distinct expression profiles in normal germline and
cancer cells, while also exhibiting differential DNA binding
activities and varying transcriptional properties. Thus, BORIS is
expressed as a repertoire of alternative transcripts and proteins,
indicating that alternative splicing generates a complex mecha-
nism for BORIS-mediated function in germline and cancer cells.
Results
Multiple BORIS transcripts are expressed in human testis,
ES cells and cell lines from different types of cancers
We previously demonstrated that expression of BORIS is
restricted to testis tissues and cancer cells, with expression
dependent on the CpG methylation status of alternative BORIS
promoters [8,16]. In analyzing CTCF and BORIS expression in
human testis, embryonic stem (ES) cells, and several cancer cell
lines by RT-PCR, we were able to amplify the full-length ZF-
encoding regions of both genes. Only a single PCR band specific
for the CTCF ZF domain was detected in all cell types examined;
however, multiple PCR bands were generated by primers
amplifying the BORIS region corresponding to ZF domain
(Fig. 1A). Sequence analyses of cloned BORIS PCR products
identified a number of alternative transcripts with different
combinations of ZF exons that were generated due to the
utilization of alternative splice sites (Fig. 1A). The abundance
and distribution of BORIS transcript variants differed among
cancer cell lines and in testis, suggesting distinct mechanisms of
regulation of BORIS gene in normal germline and cancer cells.
Knowing that CpG hypomethylation is involved in BORIS
activation [2,8,16], we compared BORIS expression in the
HCT116 colon cancer cell line to HCT116 cells treated with
5aza-dC, and to HCT116 bearing a double knockout (DKO) of
DNMT3b and DNMT1 [21]. A dramatic decrease in CpG
methylation in HCT116 DKO and HCT116 cells treated with
5aza-dC, described previously [21], correlated with the appear-
ance of multiple BORIS-specific RT-PCR products (Fig. 1A),
which were absent in the parental HCT116 cell line. Interestingly,
human ES cells were found to express at least two alternative
BORIS transcripts, confirming BORIS expression in ES cell lines as
demonstrated previously by immunofluorescence [22]. We
therefore conclude that while CTCF is expressed as a single
transcript in human testis and cancers, BORIS is expressed as
multiple isoforms in the testis, ES cells and in cancer cell lines,
specifically in cells with increased DNA hypomethylation.
Twenty three alternatively spliced BORIS isoforms are
expressed in testis and in cancer cells
Prompted by our previous identification of five alternative 59-
UTR splicing BORIS variants generated from three alternative
BORIS promoters (A, B and C) [16], we conducted a screen for
full-length alternatively spliced BORIS transcripts in human testis
and the K562 cancer cell line, the cells with the highest levels of
BORIS expression. To isolate full-length BORIS alternative
transcripts, we utilized the 39-RLM-RACE approach shown in
Figure 1B. We amplified multiple BORIS RT-PCR products that
were then cloned and sequenced (Fig. 1C). From this, we identified
19 previously unknown BORIS splice variants (Fig. 2). The two
main sources of heterogeneity in BORIS mRNAs were the usage of
alternative promoters and splice sites. We also observed differen-
tial usage of distinct 59- and 39-UTRs as well as alternative
translation frames in the amino- and carboxy-terminal coding
regions. Alignment of the BORIS genomic sequence with
alternative transcripts revealed that exon-intron boundaries had
classic splice site sequences (Table S4). Most of the alternative
BORIS transcripts possessed a polyA tail located 20–30 bp
downstream from the canonical polyadenylation signal, AAUAAA
(File S1), indicating that BORIS isoforms reached the stage of
expression as mature mRNAs.
The BORIS isoforms were categorized according to promoter
usage (Fig. 2A). Isoforms driven from promoter A included BORIS
A1, A2, A3, A4, A5, and A6. Compared to the originally described
BORIS transcript [2], which is now designated as the BORIS B0
isoform, isoforms A1 and A2 contained alternative 59 UTRs, but
encoded the same BORIS polypeptide (Fig. 2A, Table S3).
Isoform A3 had several new features that distinguished it from B0
including a long non-coding 59 UTR and the exclusion of exon 6
due to alternative splicing. This resulted in the presence of only 9
ZFs, rather than the 11 of BORIS B0, but also produced a new
long spacer between ZF5 and ZF8 (Fig. 2A, C). For isoforms A4
and C2, which both encode the same polypeptide, ORFs continue
into intron 4 until an alternative stop codon resulted in the
Alternative BORIS Transcripts
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COOH-terminus. Isoforms A5 and A6 both encoded 10 full ZFs
and half of ZF11, which is alternatively spliced from exon 8 to new
exons 9a or 9a(1), respectively, resulting in two alternative
carboxy-termini. The isoform B1 has the same 10 coding exons
as the BORIS B0 prototype, but possessed an additional exon 11,
which encoded an alternative carboxy-terminus. In addition, some
isoforms had alternative amino-termini due to the utilization of
different start codons, which result from alternative splicing of
exon Eb to exon 2 (in B3 and B4) or to exon 3 (in B2, B5, B6, B7).
Most surprisingly, only 7 out of 23 BORIS isoforms encoded a
full-length 11 ZF DNA binding domain, with the number of ZF in
the other isoforms ranging from 1 to 10 (File S1, Table S3). As
shown by the following examples, reductions in the numbers of
ZFs resulted from the utilization of alternative splice sites and stop
codons. The isoform C5 had only one ZF and an alternative
carboxy-terminus resulting from splicing from the middle of exon
3 to exon 10b. While isoform C8 contained all 11 exons, the
presence of an additional exon 6a with an in-frame stop codon
resulted in just six ZFs. Remarkably, splicing from exon 4 to exon
8 in isoform C6 created a new hybrid ZF comprised of half of ZF 4
and half of ZF 9. This raises the possibility that the new ZF could
confer new DNA binding properties to this isoform (Fig. 2B).
Finally, some alternative exons, such as 5a in B6, B7, C7, and C9,
retained intronic sequences that incorporated premature stop
codons, and therefore may not produce stable protein due to the
nonsense-mediated mRNA decay (NMD) pathway, a possibility
that should be verified experimentally.
Characteristic features of BORIS alternative variants and
their evolutionary conservation in humans and non-
human primates
The 23 BORIS mRNA splice variants have the potential to
encode 17 different polypeptides that we designate as BORIS
isoform proteins 1 through 17. To categorize the isoforms, the
alternative amino- and carboxy-termini were named according to
the number of amino acid residues upstream and downstream of
the ZF domain, respectively (Table S3). For example, N258
denotes an amino-terminus with 258 amino acid residues
upstream of the ZF domain that is encoded in many BORIS
isoforms including B0, B1, A3, A4, A5, A6, C3, C4, C5, C6, C7/C9
and C8. Notably, N24 and N53, truncated versions of N258, have
no amino acid differences with N258 within the 24 and 53 amino
acids upstream from ZF1. Eleven alternative carboxy-termini
found in distinct isoforms are designated as ‘‘C’’, with their
numbers corresponding to the number of codons downstream of
the last ZF. For example, B1 has C132, C3 has C97, C5 has C53,
etc. (File S1, Table S3).
To search for homology with known proteins or domains, the
eleven unique alternative C-termini were compared by BLAST to
GenBank amino acid sequences. Only one alternative carboxy-
terminus, C97, showed a significant degree of similarity with
multiple non-BORIS proteins, including several involved in the
processes of transcription or translation (Fig. S2). This newly
recognized putative domain is a previously uncharacterized
component of a known helicase-like domain (COG0553). Further
analyses of alternative 39UTRs of some isoforms revealed the
presence of specific repetitive DNA elements. For example, a part
of the 39UTR for the B6 and C7 isoforms belongs to an Alu-J
consensus. The 39UTR of isoform B1 is also highly repetitive in
human and primate genomes. Isoforms C3, B2, B3, C4, C5, and C8
have the primate-specific repetitive DNA element, MER1 [23] in
their 39UTRs.
The fact that BORIS isoforms are conserved in other species
suggests their biological significance. For example, all features of
human BORIS isoforms are highly conserved in the apes Pan
troglodytes and Macaca mullata, with conserved splice sites and
corresponding protein identities ranging from 96% to 100% and
from 53% to 97%, respectively (Fig. 3). Among the most conserved
C-termini are: C95 (with identities of 99% and 89% in
chimpanzee and macaques, respectively), C97 (97% and 91%),
Figure 1. RT-PCR of alternatively spliced BORIS transcripts in
human testis, ES cells and cancer cell lines. (A) Total RNAs from
the indicated cell lines and testis tissue were analyzed by RT-PCR using
primers designed to amplify the full-length CTCF and BORIS ZFs
domains. The sequences of primers are shown in Table S1. Nested PCR
was performed with 20 and 35 cycles for first and second rounds,
respectively. The sources of RNA are shown on top of each gel. Arrows
point to the single CTCF transcript and multiple BORIS alternative
transcripts. (B)3 9 RLM-RACE strategy for cloning alternatively spliced
BORIS forms. Three BORIS alternative promoters and 12 exons with
noncoding sequences (white boxes) or coding sequences (grey boxes)
are shown. Total RNA from adult human testis and the K562 cell line
was processed with GeneRacer PCR kit for the amplification of full-
length cDNAs. The first round of PCR was performed with three forward
gene-specific (GSP) primers A, B, and C that were designed to identify
mRNA expressed from corresponding alternative BORIS promoters A, B
or C, respectively. The 39 GeneRacer primer attached to the poly A tail
was used as a reverse primer. l ml of the first-round PCR mixture was
used as a template to perform nested PCR with three forward nested
gene-specific (NGSP) primers A1, B1, and C1. (C)3 9 RLM-RACE was
performed on human testis and the K562 cell line. Multiple BORIS
transcripts were detected in both samples. PCR products of the nested
PCR are shown separated on 1% agarose gels. M is the size marker.
doi:10.1371/journal.pone.0013872.g001
Alternative BORIS Transcripts
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96%). C132 is highly conserved in the chimpanzee (96%), but less
so in macaques (53%). While alignment of human BORIS isoforms
with the mouse genomic locus uncovered several putative mouse
BORIS carboxy-termini (C95, C90, C35, and C34), the homology
levels were rather low, ranging from 9% to 42%. This suggests that
the pace of BORIS evolution in mammals has been quite rapid and
the complexity of BORIS locus likely coincided with the emergence
of primates. The fact that the mouse Boris locus does not have the
same range of isoforms as humans or other primates may be
related to primate-specific evolution of intron sequences of BORIS
loci [18]. It remains to be determined whether mice have
alternative Boris isoform species. If they exist, it should be
anticipated that they would be distinct from those of humans
despite the conservation of splice sites. The emergence of isoforms
in primates may thus be attributed to putative intronic splicing
enhancers.
Alternative BORIS transcripts are expressed in normal
male and female gonads
We previously reported that expression of BORIS B0 in normal
human tissues was restricted to testis [2]. To analyze the patterns
of BORIS isoform expression in testis, we designed a series of
primers and Taqman probes to amplify the alternative transcripts
by qRT-PCR. Only 8 of 23 BORIS isoforms could be specifically
discriminated by qRT-PCR because most isoforms share sequenc-
es, making it impossible to design primers and probes that would
detect every BORIS isoform as a separate species. Consequently,
we operationally divided the 23 isoforms into six subfamilies (sf1 to
sf6) based on their unique 39 terminal sequences, which were used
to design 6 Taqman probes for qRT-PCR (Fig. 2A, Materials and
Methods). Among 13 adult and 13 fetal tissues tested, expression of
the six BORIS subfamilies was detected only in adult testis and in
embryonic ovary, but the relative levels of isoform expression were
reproducibly different in the two tissues (Fig. 4A,B). In adult testis,
all six subfamilies were expressed at comparable levels, with sf1
being the most prevalent group, expressed at approximately 1.3- to
3-fold higher levels than the other five subfamilies (Fig. 4A). In
contrast, sf3 was the most prevalent form in embryonic ovaries
(Fig. 4B), being expressed at levels approximately 4-fold higher
than sf1 and sf4, and 11- to 127-fold higher than the sf6, sf2, and
sf5 groups (Fig. 4B). While among adult tissues only testis was
strongly positive for BORIS isoforms, they were expressed at very
low albeit reproducible levels in several tissues in the fetal panel,
including testis, skin, and spleen (Fig. 4B). This suggests that
BORIS isoforms may be functionally active outside the germline
during fetal development.
To identify the specific cell types that express BORIS isoforms in
adult testis, we carried out RNA in situ hybridization using fixed
preparations of normal human testis. Immunostaining of testis
with antibodies to SCP3 and E-cadherin was used to distinguish
spermatogonia and spermatocytes, respectively, while spermatids
were identified morphologically as small and elongated cells with
elongated nuclei (Fig. 4C, E-cad, SCP3). Following hybridization
to six labeled PCR probes designed to specifically detect each of
the six BORIS subfamilies, isoform transcripts were detected at
nearly all stages of spermatogenesis (Fig. 4C). All six BORIS
transcript subfamilies were less abundant in the cytoplasm of
spermatogonia than spermatocytes, while spermatids were highly
positive for BORIS sf2 and marginally positive for sf5 and sf6.
Thus, sf2, sf5 and sf6 appear to characterize the later stages of
spermatogenesis from spermatocytes to spermatids. A previous
study [2] using chicken anti-BORIS antibody and a 59 end-labeled
BORIS probe, both specific for the N258 terminus, showed that
expression of the BORIS B0 isoform was restricted primarily to
spermatocytes. The present work complements our previous
assessment of BORIS transcript localization by providing evidence
for the expression of all six BORIS subfamilies in adult human
testis. The apparent differential expression of individual subfam-
ilies during the progression from early to later stages of
spermatogenesis indicates that expression of BORIS isoforms is
developmentally regulated.
BORIS isoforms encode putative cancer-testis antigens
Previous studies showed that the BORIS B0 isoform is
abnormally expressed in many types of human cancers, including
both primary cancers and cancer cell lines, qualifying it as
encoding a putative cancer-testis antigen (CTA) [6,8,24,25,26]. To
understand the relevance of the newly discovered multiple BORIS
isoforms to cancer development and progression, we tested the
NCI-60 cancer cell line panel by RT-PCR and found that about
70% of those cell lines expressed transcripts of some isoforms
(Fig. 5A). Most of the positive lines, however, expressed levels of
BORIS transcripts that were quite low at less than 500–1,500
transcripts per 50 ng of total RNA. Nevertheless, the levels were
sufficient to detect two distinct patterns of BORIS isoform
expression. The first pattern, exemplified in Figure 5B for the
K562 cell line, was associated with more than 20,000 BORIS
transcripts (summed over all six BORIS subfamilies) per 50 ng of
total RNA. In this subset of cell lines (8 out of 60, 13% of the NCI-
60 panel), sf1 transcripts were present at the highest levels,
averaging about 3-fold higher than levels for sf2, 10-fold higher
than for sf3 and sf4, 50-fold higher than for sf6, and more than
100-fold higher than for sf5 (Fig. 5B). The cell lines showing this
expression pattern originated from different tissues, including
ovary, lung, breast, blood, and skin, indicating that expression of
BORIS isoforms is not specifically associated with cancers of
particular origins.
More than 50% of the positive cell lines from the NCI-60 panel
exhibited a second pattern of BORIS isoform expression. This
pattern, exemplified by the Ovcar 3 cell line (Fig. 5C), was
characterized by less than 20,000 summed BORIS transcripts per
50 ng of total RNA. Unlike the first pattern, five of the six
subfamilies were expressed at approximately equal levels, while sf5
showed notably lower level of expression (Fig. 5C). Furthermore,
the pattern of differential expression is even more complex, as
some BORIS isoforms belonging to a single family were not
expressed equally, with some more abundant than the others. This
Figure 2. Organization of the human BORIS gene with alternative BORIS transcripts. (A) Schematic illustration of the BORIS gene with three
alternative promoters and sixteen exons used for generation of 23 isoform mRNAs. Exons sizes are shown under the scheme, with minimum and
maximum number of nucleotides for the alternative exons. The start and stop codons for ORFs are indicated as ATG and Stop, respectively. The first
BORIS transcript represents the originally cloned BORIS form, designated here as B0; the BORIS transcripts shown below are novel cloned isoforms. On
the left are the names of BORIS isoforms, corresponding to schematic representation of given transcripts. On the right, the six BORIS subfamilies,
divided on the basis of similar 39 ends, are indicated. The red and blue lines on the top or bottom of the schematic representation of isoforms depict
the locations of Taqman probes. Untranslated regions are represented by open boxes. Introns (thin lines) are not shown to exact scale. (B) Alternative
splicing creates a new ZF in the C6 isoform. Amino acid sequence comparisons of ZF 4 of B0 and new alternative ZF 4/9 of C6, which combines the
first half of ZF 4 and the second half of ZF 9. (C) Alternative splicing creates a new coding spacer between ZFs 5 and 6 in A3 isoform.
doi:10.1371/journal.pone.0013872.g002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13872Figure 3. Human BORIS isoform amino acid sequences are evolutionarily conserved in primates. (A) Percent identity of human (H.sapiens)
BORIS isoforms C-termini to putative alternative amino acid sequences those of chimpanzee (P.troglod.), macaque (M.mulatta), and mouse (M.mus.).
Elevenalternative C-termini found in distinct isoforms aredefined by the number of codons downstream of the last ZF. Thetable showsnames of BORIS
isoforms with corresponding C-termini and their identity in percent. (B) Alignment of BORIS alternative C-termini in human, chimpanzee, macaque and
mouse. The alternative amino acid sequences of human, chimpanzee, macaque and mouse are aligned by ClustalW (Vector NTI). Human BORIS splice
variants are highly conserved in primates, but not in mice. Amino acid sequences for some of BORIS alternative C-termini (C132, C97, C68, C53, C36, C30,
C24) are completely absent in mice. Yellow highlighted sequences are 100% identical to the human amino acid sequence; the blue highlight indicates
conservative substitutions relative to human homologous BORIS sequences. Dots indicate insertions or deletions.
doi:10.1371/journal.pone.0013872.g003
Alternative BORIS Transcripts
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subfamilies (File S2, Fig. S4).
To confirm the expression of BORIS isoforms in cancer cell lines
and testis by independent means, we used both northern blotting
(File S2, Fig. S4) and Ribonuclease Protection Assay (RPA)
(Fig. 5D–J). Both are extremely specific methods for detecting and
quantifying RNA species. For RPA, five riboprobes spanning the
unique regions of BORIS subfamilies were used, along with one
riboprobe to detect the rearrangement of zinc fingers in the ZF
binding domain of isoform C6. The protected bands in RPA
Figure 4. Expression of BORIS alternative transcripts in male and female gonads. qRT-PCR analysis of BORIS isoform expression in normal
human adult (A) and fetal (B) tissues, respectively, was quantified by the absolute quantification approach. The 23 BORIS isoforms were divided into 6
subfamilies based on their unique 39 end sequences to enable the design of Taqman probes (Material and Methods). (C) BORIS isoform expression in
human normal adult testis analyzed by in situ hybridization, RNA FISH. For FISH assays, the probes for six BORIS subfamilies (sf1–sf6) were labeled with
digoxygenin-11-dUTP by PCR and individually hybridized to formaldehyde-fixed adult human testis. The slides were incubated with anti-DIG
antibodies overnight and then visualized with rhodamine-conjugated secondary antibody. To identify spermatogonia and spermatocytes, we
performed immunostaining with antibodies against SCP3 (red) and E-cadherin (light green), respectively. Merged images of DAPI-stained nuclei
(blue) and BORIS isoform RNA (red) taken with 20X magnification; higher magnification images are 63X. Arrows with letters indicate: Sg-
spermatogonia, Sc – spermatocytes, St – spermatids (small, elongated cells with elongated nuclei, respectively). The control (Ctr) is staining with
rhodamine-conjugated secondary antibody alone.
doi:10.1371/journal.pone.0013872.g004
Alternative BORIS Transcripts
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13872Figure 5. Expression of BORIS isoforms in cancer cell lines. (A) The BORIS subfamilies are significantly upregulated in cancer cells as compared
to normal cells. For normal cells (N) – the expression of BORIS isoforms was analysed in 13 tissues and 4 primary cell lines. For tumor cells (T) - the NCI-
60 cancer cell lines were analyzed. 59 of the NCI-60 cancer cell lines, 13 normal tissues, and 4 normal primary cell lines were analyzed by the absolute
quantification approach with normalization to GAPDH levels, and plotted using a logarithmic scale. Levels of BORIS isoform expression vary greatly
(from 0 to 60000 transcripts per 50 ng of total RNA). Red lines indicate mean values for each BORIS subfamily. (B) The first pattern of BORIS isoform
expression in NCI-60 cancer cells, as represented by the K562 cancer cell line. (C) The second pattern of BORIS isoforms expression in NCI-60 panel is
exemplified by the Ovcar3 cancer cell line. (D-J) BORIS isoforms expression analyzed by RPA. Aliquots of total RNA obtained from kidney, testis and
K562 cell line were hybridized with
32P–labeled antisense RNA probes. The RNase protected fragments (arrowheads) were detected only in testis and
K562, but not in kidney. The first lane on each gel is a control, an undigested probe incubated with yeast RNA. (D) RPA with riboprobe sf1/sf5 yields
Alternative BORIS Transcripts
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either testis or the K562 cell line; all six probes were fully digested
when incubated with kidney RNA(Fig. 5D–J). These results
confirm the Real-Time PCR data and the assignment of BORIS
isoforms to the CTA family. The sizes of fully protected major
bands correspond to sf1 (154 bp), sf2 (149 bp), sf3 (153 bp), sf4
(146 bp), sf5 (40 bp), sf6 (163 bp), and C6 (158 bp) (Fig. 5D–J).
Furthermore, due to the overlapping sequences among BORIS
subfamilies, several smaller bands corresponding to the protected
fragments of other subfamilies/isoforms were present on one gel.
For example, the riboprobe sf1/sf5 (Fig. 5D), which spans coding
and noncoding sequences of exon 10, protected two bands of
154 bp and 40 bp, indicating the transcrption of sf1 and sf5
transcripts, respectively, in both testis and the K562 cell line.
Similarly, the sf2 probe protected 149 bp of sf2 and 51 bp of exon
4 coding sequence that presents in most BORIS subfamilies,
documenting the relatively equal and low expression, compared to
other subfamilies, of sf2 in testis and the K562 cell line,
respectively, (Fig. 5E). The sf3 riboprobe specifically protected
153 bp of the A5, B4, and C6 isoforms of sf3, 117 bp of the B5 and
A6 isoforms of sf3, and 36 bp of exon 8, revealing relatively low
expression of sf3 when compared to the total transcripts for sf1, sf4
and sf5 (Fig. 5F). The sf4 probe detected only subfamily 4,
resulting in a single protected fragment of expected size (Fig. 5G).
The riboprobe sf6 yielded 163 bp of sf6 and 46 bp of exon5,
present in most BORIS isoforms (Fig. 5H) The C6 riboprobe
detected alternative (185 bp) and originally-described (85 bp and
75 bp) splicing in ZF region of BORIS (Fig. 5I). Thus, the results
from RPA analyses of BORIS subfamily expression were in close
agreement with Real-Time PCR data, demonstrating the
dominant expression of sf1 in K562 and relatively equivalent
expression of BORIS subfamilies in testis.
An additional search for BORIS-related expressed sequence tags
(ESTs) in DNA sequence databases revealed that BORIS sf2 is
expressed in primary and metastatic Wilms’ tumors (Table S5).
Moreover, BORIS sf1 was found to be expressed in many types of
primary cancers, including retinoblastoma, chronic myelogenous
leukemia, and mucoepidermoid carcinoma (Table S5). Thus,
BORIS isoforms were aberrantly activated not only in established
cancer cell lines, but also in primary cancers of different origins.
The 23 alternatively spliced mRNA variants encode 17
alternative nuclear BORIS proteins
To determine whether BORIS isoforms are translated and to
examine their subcellular localization, 17 ORFs corresponding to
17 alternative BORIS proteins (Table S3) were cloned as amino-
terminal HA-tag fusions into mammalian expression constructs
based on the pCI vector. Following transient transfection into
HEK293T cells, immunoblotting with anti-HA-Tag antibodies
showed that all BORIS isoforms, when expressed ectopically, were
translated into proteins of expected molecular mass (Fig. 6A).
Some BORIS isoform proteins, refered to as isoproteins here, such
as B0, B1, A6, A5, C3, and B4, were expressed more efficiently
than others, indicating enhanced stability of these proteins.
BORIS protein, identified by an antibody that could potentially
detect multiple BORIS isoforms, was previously reported to
localize to both the nucleus and the cytoplasm of primary
spermatocytes [2]. This prompted us to characterize the
subcellular localization of individual BORIS isoproteins.
HEK293T cells, primary normal human dermal fibroblasts
(NHDF), and the colon cancer cell line, HCT-15, were transiently
transfected with expression constructs bearing fusions of BORIS
isoform ORFs with the coding region of the modified red
fluorescent protein, DsRed. The localization of BORIS isoforms
was restricted to the nucleus in all three cell types at 24 h and 48 h
after transfection (Fig. 6B and Fig. S3). Control transfections with
a DsRed-expressing vector demonstrated uniform expression of
RFP throughout the cell, while CTCF fused to GFP localized
exclusively to the nucleus. Under higher magnification, multiple
red fluorescent spots were detectable inside the nucleus for all
BORIS isoforms (Fig. 6B and Fig. S3). The patterns of BORIS
isoform expression in the nucleus were thus very similar to the
punctate pattern described previously [22,27]. The nuclear
localization of BORIS isoproteins is consistent with the idea that
they bind DNA and/or regulate some processes in chromatin.
A subset of BORIS isoform proteins binds the human H19
ICR in a methylation-sensitive manner
Since many BORIS isoproteins possess a ZF DNA binding
domain that is highly similar to that of CTCF, their expression in
the same cell could interfere with the binding of CTCF to its
targets. To investigate the ability of BORIS isoforms to bind to
CTCF target sites, we conducted EMSA with the sixth CTS of the
IGF2/H19 ICR, which has been shown to correlate with
monoallelic expression of IGF2 and H19 [28]. As shown in
Figure 7A, nine of seventeen in vitro translated BORIS isoproteins
(B1, B2, B3, B4, B5, A5, A6, C3) and full length CTCF as a
control, bound DNA, evidenced by the specific retardation of the
labeled H19 ICR probe. The negative control, luciferase, as well as
the remaining eight BORIS isoforms (B6, A3, A4, C4, C5, C6, C7,
C8) were inactive in EMSA with this probe.
These findings indicate that the first nine ZFs of the BORIS
DNA binding domain are required for binding to the sixth CTCF
target site in the IGF2/H19 ICR in vitro. The alternative amino-
and carboxy-termini apparently have less prominent roles in the
DNA binding activities of these isoforms. However, the particular
gel migration shifts of BORIS-DNA complexes appeared to be
specific for the individual amino- and carboxy-termini. For
example, isoproteins B0, B1, A5, A6 and C3, all having the
N258 terminus, produced one dominant, highly shifted band,
comparable to the shift seen with full-length CTCF (Fig. 7A). At
the same time, the truncated version of the N258 terminus found
in isoproteins B2, B3, B4, and B5 was associated with multiple
much lower band-shifts that may also be attributable to different
alternative carboxy-termini. Notably, two of the four band-shifts of
isoprotein B3, having the N53 terminus, were similar to two of
those of B4, while the two higher band-shifts were observed only
for B3. This difference between the B3 and B4 isoproteins is likely
conferred by two distinct carboxy-termini, C97 and C90,
respectively, indicating that C97 is responsible for two additional
EMSA bands and probably for a substantially different DNA-
BORIS complex. This view is supported by analyses of the binding
of isoproteins B2 and B5 to DNA, as B2, which has C97, resulted
in a band shift similar to B3 (Fig. 7A). Thus, both amino- and
carboxy-termini appear to influence the migration and, putatively,
the structure of BORIS-DNA complexes, which may lead to
154 bp and 40 bp fragments, corresponding to sf1 and sf5, respectively. (E) The sf2 probe protects 149 bp of sf2 and 51 bp of exon 4. (F) The sf3
riboprobe protects 153 and 117 bp of sf3. (G) The sf4 riboprobe protects 164 bp sequence of sf4. (H) The sf6 riboprobe yields 163 bp of sf6 and
49 bp of exon 5. (I) The C6 riboprobe demonstrates alternative (158 bp) splicing in ZF region. (J) GAPDH probe was used as a loading control. This
experiment was repeated twice with consistent results.
doi:10.1371/journal.pone.0013872.g005
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target.To evaluate the effect of DNA methylation on the binding
activities of BORIS isoforms, we performed EMSAs using a H19
ICR probe with CpGs methylated in vitro by SssI methyltransfer-
ase. As shown in Figure 7B, binding of CTCF and all BORIS
isoforms to the methylated ICR was completely abrogated by CpG
methylation. This finding was highly reproducible and contrasts
with an earlier study that reported methylation-independent
binding of BORIS to the IGF2/H19 ICR [29]. Thus, binding of
BORIS isoproteins to DNA, at least to the H19 ICR probe, is
methylation-sensitive, as shown previously for CTCF. These
results suggest that CTCF and BORIS isoproteins may be
functionally relevant competitors for target sites in vivo as well as
lend support to the proposed role for BORIS in the regulation of
imprinting in primary spermatocytes and round spermatids where
CTCF is not expressed [2].
BORIS proteins bind to the testis-specific promoters of
human and mouse CST genes
We recently identified a unique testis-specific promoter for the
mouse CST (cerebroside sulfotransferase) gene as a target
transcriptionally regulated by BORIS [9]. In EMSA assays, a
120 bp human CST promoter probe was specifically shifted by 13 of
17 BORIS isoproteins (Fig. 8B,C). Because of the high conservation
of this target site between human and mouse CST genes (Fig. 8A),
BORIS isoforms bound comparably to both the human and mouse
CST DNA probes (Fig. 8B,C). As for binding to the H19 ICR, the
binding of BORIS isoforms to the CST probe was unaffected by
alternative amino-and carboxy-termini,whereasthedegreeofband
migration generally correlated with specific protein termini.
Figure 6. BORIS isoforms are translated into proteins with
nuclear localization in vivo. (A) Immunoblotting detection of
ectopically expressed BORIS isoform proteins. Expression vectors with
HA-Tag fused BORIS isoforms were transiently transfected into HEK293T
cell line. The transfection efficiency, monitored by co-transfection with a
GFP-expressing plasmid, was similar for all transfected plasmids. Total
protein was extracted, separated on a 12% SDS-PAGE gel, and probed
with rat monoclonal anti-HA antibody (Roche). Molecular mass
standards are on the left. The sizes (in kDa) of BORIS isoform proteins
correspond to thier predicted molecular masses, as shown in Table S3.
(B) Nuclear localization of CTCF, B0, and C5 isoproteins. The localization
of the rest BORIS isoproteins is shown in Fig. S3. HEK293T cells
transiently transfected with either BORIS or CTCF fused at the N-
terminus to dsRFP or GFP, respectively, were analyzed for RFP and GFP
fluorescence by microscopy. dsRED protein (Empty Vector (EV)-dsRED)
served as a marker for cytoplasmic location. Cells were also stained with
DAPI to visualize nuclear DNA. Both BORIS and CTCF were detected in
the nuclei.
doi:10.1371/journal.pone.0013872.g006
Figure 7. BORIS isoforms bind to the human IGF2/H19 ICR in a
methylation-sensitive manner. (A) Binding of in vitro translated
BORIS isoforms to the sixth CTCF target site in the human H19 ICR by
EMSA. In vitro translated CTCF and luciferase proteins were used as
positive and negative controls, respectively. The DNA-protein shifts
corresponding to the particular N- termini are indicated by arrows. The
number of ZFs and alternative N-and C-termini for each isoform are
indicated at the bottom of gel. (B) DNA binding of BORIS isoforms to
the H19 ICR is methylation-sensitive. EMSA of BORIS isoform binding
performed with SssI-methylated H19 ICR probe shows that none of 17
BORIS isoforms bound to the methylated H19 ICR. The left panel shows
the quality control of the methylated probe by digestion with
methylation-sensitive restriction endonuclease AciIo f
32P-labeled
methylated and unmethylated H19 ICR probes.
doi:10.1371/journal.pone.0013872.g007
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13872Figure 8. BORIS isoforms bind and activate the transcription of conserved human and mouse CST testis-specific promoter regions. (A)
Schematic representation of multiple mouse CST promoters, where exon 1fs has been shown to be testis specific [48] and the BORIS binding site has been
mapped to the testis-specific CST promoter [9]. The alignment of human and mouse BORIS binding site in CST promoter is shown at the bottom. The 5
cytosinesboxedinthealignmentarecontactnucleotidesforBORISproteinasitwasdeterminedbymethylationinterferenceassays[9].Nucleotidesthat are
100% identical to the human nucleotide sequence are shaded in grey. Dashes indicate insertions or deletions. (B)a n d( C) Most BORIS isoforms bind to the
human and mouse testis-specific CST promoter in EMSA. The number of ZFs and utilization of alternative N-and C-termini for eachBORIS isoform are shown
atthebottomofgel.ThebandshiftsspecificforparticularN-andC-terminiareindicatedbyarrows.LuciferaseandCTCFwereusedasnegativeandpositive
controls, respectively. (D) The mouse CST promoter is transcriptionally activated by BORIS isoforms in HEK293T cells. HEK293T cells were either co-
transfected with mouse Boris, mouse Ctcf, empty pCI vector (EV) or the human BORIS isoform constructs, as well as with pGL-3 containing 359 bp of wild
type or mutant CST promoter. Luciferase assays were done 48 h after transfections. All luciferase activities were normalized for transfection efficiency by
measuring the Renilla luciferase activity from the co-transfected pRL-TK vector. Error bars are standard deviations.
doi:10.1371/journal.pone.0013872.g008
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proteins (A3, C4, C7 and C8) than the probe for the H19 ICR
(Fig. 7A and Fig. 8B,C). This difference in target specificity could
be ascribed to the number and composition of ZFs in the DNA
binding domain of a specific isoprotein. For example, while nine
ZFs were required for binding of BORIS isoproteins to the H19
ICR, only five were required to bind the CST probe. BORIS
isoproteins bound to the CST probe also produced fewer
additional band-shifts compared to those seen on binding to the
H19 ICR. The B6, A4, C5 and C6 isoproteins did not bind the
CST probe (Fig. 8B,C). C6, which has a hybrid ZF4/ZF9 zinc
finger (Fig. 2B), did not bind the CST promoter, despite having a
total of 5 ZFs, as many as isoproteins C4 and C7 (Fig. 2A and
Fig. 8B,C). This reinforces the suggestion that properties of
individual ZFs are important for DNA binding specificity and
provides additional evidence for potential functional distinctions
among isoproteins in vivo.
Finally, if binding of the H19 ICR and CST promoter by CTCF
and BORIS isoproteins is compared using the same reaction
conditions, BORIS isoforms bind the H19 ICR comparably to
CTCF (Fig. 7A). At the same time, binding of CTCF to the CST
probe was evidently much weaker than that of BORIS isoproteins
(Fig. 8B,C). This suggests that target preference for different DNAs
is characteristic not only of BORIS isoproteins, but also
discriminates between BORIS isoproteins and CTCF.
BORIS isoproteins are potential transcriptional activators
of the testis-specific CST promoter
The fact that some BORIS isoproteins can bind the same
targets as CTCF (Fig. 7 and Fig. 8) prompted us to determine if
the functional consequence of binding to a given target would be
comparable for both CTCF and BORIS isoproteins. The potential
to regulate transcription is one functional readout of such binding.
To this end, we transiently co-transfected a luciferase reporter
under the control of either a wild type or a mutant mouse CST
promoter together with expression constructs for mouse Boris and
Ctcf, and each human BORIS isoform (Fig. 8D). The wild type CST
promoter was activated more than 3-fold by co-transfection of
human BORIS isoforms B0, B1, A5, A6 and C3 (Fig. 8D).
Isoforms A3 and C8 showed were at least 1.5-fold more active on
the CST promoter. The most potent activator was the full-length
mouse BORIS protein, while mouse CTCF was relatively inactive
(Fig. 8D) despite its ability to form a CST-CTCF complex in vitro
(Fig. 8B,C). Thus, the functional outcomes of CTCF and BORIS
isoform binding to the same target can differ and may reflect a
specific biologic role of BORIS in the regulation of some genes,
such as CST, that are co-expressed with BORIS in testis.
BORIS isoforms that bound both the mouse and human CST
probes in EMSA (Fig. 8B,C) and had the long N258 amino-
terminus in common were able to activate the CST promoter in
vitro, indicating that N258 contains a transcriptional activation
domain. Accordingly, isoforms B2, B3, B4 and B5 that lack N258
could bind to CST (Fig. 8B,C), but did not induce transcription
above background (Fig. 8D). Thus, a ZF domain with a short
amino-terminus and alternative carboxy-termini is not sufficient to
activate transcription. In parallel with the wild type CST promoter,
we used a CST promoter with mutations of contact nucleotides
that abrogate BORIS binding. We observed that the mutant
promoter, although driving luciferase expression less efficiently
than the wild-type promoter, was nonetheless clearly unresponsive
to co-transfection with BORIS isoproteins, solidifying the evidence
for DNA target sequence specificity of BORIS isoforms as a
requirement for activation of the CST promoter.
DNA methylation, p53 and CTCF are responsible for
BORIS isoform repression in somatic cells
The genome-wide pattern of DNA methylation is a key
framework of epigenetic phenomena in humans [17]. Recently,
CTCF was shown to play key role in maintenance of DNA
methylation patterns in normal differentiated cells [30,31].
Moreover, demethylation of normal human fibroblasts induced
by 5aza-dC results in the activation of BORIS B0 expression [8].
Furthermore, as shown in Figure 4C, BORIS isoforms are highly
expressed in spermatocytes of adult human testis where the levels
of CpG methylation are known to be reduced [2]. Demethylation
of the BORIS promoter was also linked to BORIS expression in
cancers [16,27,32]. Therefore, we tested whether BORIS isoforms
could be activated by treating human fibroblasts with 5aza-dC or/
and the histone deacetylase inhibitor, TSA. All six BORIS
subfamilies were effectively activated in cells treated with both
agents together (Fig. 9A). sf1 appeared to be more responsive to
DNA demethylation than the other subfamilies, an observation in
keeping with pattern 1 of BORIS isoform expression in cancer cell
lines illustrated in Figure 5B.
To independently verify that BORIS isoforms could be activated
by DNA demethylation, we analyzed their expression in four
variants of the HCT116 colon cancer cell line: the parental cell
line; the single knockouts (KO) of DNMT1 and DNMT3B in which
DNA methylation is reduced 20% and 3%, respectively; and the
double knockout of DNMT1 and DNMT3B with genomic
methylation reduced by 95% [21]. The transcript levels of BORIS
isoforms in the parental cell line were used as a baseline to evaluate
the effects of DNA demethylation. The modest reduction of DNA
methylation characteristic of DNMT3b KO cells was not sufficient
to activate BORIS transcription, while the greater reduction of
DNA methylation in DNMT1 KO cells was associated with low
level activation of all BORIS subfamilies. The highest levels of
BORIS isoform expression were observed in the double KO cells,
confirming the idea that DNA methylation has a cumulative
repressive effect on expression of BORIS isoforms (Fig. 9B). sf1 was
more sensitive to DNA demethylation than the other subfamilies,
similar to results shown in Figure 9A. Thus, the efficiency with
which alternative BORIS transcripts can be activated correlated
with genomic DNA demethylation in a dose-dependent fashion.
This dependence likely reflects a direct contribution of DNA
methylation to transcriptional repression of BORIS in somatic cells.
In addition to DNA methylation, both CTCF and p53 have
been shown to repress transcription of BORIS B0 [8,16].
Furthermore, multiple methylation-sensitive and methylation-
insensitive CTCF target sites were mapped in all three BORIS
promoters [16]. To characterize the effect of CTCF downregula-
tion on expression of all BORIS subfamilies, the colon cancer cell
lines, HCT-15 and HCT-116, were transiently transfected with
CTCF siRNAs. A less than 2-fold suppression of CTCF resulted in
elevated expression of all subfamilies (Fig. 9C,D). The pattern of
BORIS isoform upregulation was similar in both cancer cell lines,
suggesting a common mechanism of BORIS isoform repression by
CTCF at least in some cancer cell lines.
Wild type p53 was previously shown to be an independent
repressor of BORIS expression with the levels of BORIS transcripts
in the NCI-60 cancer cell lines being correlated with deletion of
p53 [16]. p53 likely acts by binding to SP1 sites mapped in the
BORIS promoter [16]. To detail the effect of p53 on expression of
BORIS isoforms, we induced ectopic p53 transcription in the
H1299 lung cancer cell line, which is homozygous for deletion of
p53. While BORIS subfamilies were expressed at very high levels in
parental H1299 cells, the induction of p53 for 48 hours resulted in
strong suppression of all subfamilies, except sf5 (Fig. 9E).
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of CTCF. Thus, the suppressive effect of p53 on BORIS isoforms
may be due, at least in part, to upregulation of CTCF (Fig. 9E). In
summary, p53 effects, CTCF binding, and DNA methylation
provide three interdependent mechanisms for the complete
suppression of BORIS isoforms expression in somatic cells, as a
means of avoiding BORIS competition with CTCF for its
functions [16].
Discussion
BORIS is expressed as multiple isoforms in germ cells
CTAs are expanding family of proteins normally restricted to
germ cells that are nevertheless detected in many cancers [26]. As
a member of CTA family, BORIS is critical to normal germline
development [9] and may also play a role in oncogenic
transformation [34]. Therefore, understanding the potential roles
of BORIS isoproteins is imperative for deciphering these complex
pathways. In the present work, we demonstrate that testis-specific
mRNAs originating from the BORIS locus comprise at least 23
alternative transcripts that have the potential to encode 17 distinct
proteins with varying number of ZFs and different combinations of
amino- and carboxy-termini (Fig. 2, Fig. S1, Table S3). Alternative
splicing and utilization of alternative transcription initiation sites
can greatly expand the coding capacity of a gene, and are known
to be utilized more frequently during organogenesis of complex
organs, such as brain or testis [35]. All the structural differences
among the BORIS isoforms could prove necessary for specialized
functions in the testis, including differential binding to DNA
targets and interactions with alternative partner proteins.
As sequences of most BORIS isoforms have considerable overlap
and frequently have similar transcript sizes, it was impossible to
detect expression of each BORIS isoform by conventional methods
(Fig. 2, Fig. 5, Fig. S4, File S1 and File S2). The subdivision of the
23 BORIS isoforms into 6 subfamilies, sf1 to sf6, according to
unique 39 sequences, enabled the robust detection and quantifi-
cation of subfamily expression using 6 BORIS specific qRT-PCR
probes and RPA riboprobes (Fig. 2 and Fig. 5D-J). All six BORIS
subfamilies were expressed in adult testis with sf1 being the
dominant set. Subfamilies notably differ in their promoter usage:
sf1 and sf3 express from all three BORIS promoters; sf4 expresses
from promoters A and C; sf5 expresses only from promoter B;
while sf6 utilizes promoters A and C. The nature of the
relationship between promoter usage and isoform identity requires
further investigation.
BORIS isoforms were expressed at low levels in the early stages
of spermatogenesis, including spermatogonia, compared to the
later stages represented by spermatocytes and spermatids (Fig. 4C).
Spermatids were only slightly positive for sf5 and sf6 but were
strongly positive for sf2 (Fig. 4C). This may indicate a
developmentally controlled shift in the repertoire of isoforms,
possibly signifying distinct functions for individual isoforms during
male germline development. The characterization of specific
functions of BORIS isoforms in testis would, however, require the
Figure 9. CpG methylation, p53 and CTCF are responsible for
BORIS isoform repression in somatic cells. (A) BORIS isoform
expression is activated by 5-aza-dC treatment of Normal Human Dermal
Fibroblasts (NHDF). qPCR analyses were done on total RNA extracted
from NHDF treated with 5-aza-dC alone or in combination with
Trichostatin A (TSA). Data were analyzed by comparing Ct values and
normalized to the control (untreated cells). (B) Activation of BORIS
isoforms transcription correlates with genomic DNA demethylation.
qPCR was used to quantify BORIS subfamily expression in 4 types of
HCT116 colon cancer cell lines: the HCT116 parental cell line, two single
knockouts for DNMT1–/– and DNMT3B–/– and the double knockout
(DNMT12/2,DNMT3b2/2) (DKO). Data were normalized to BORIS
isoform levels in the HCT116 parental cell line. (C) and (D) Knockdown
of CTCF in two colon cancer cell lines results in the activation of all
BORIS subfamilies. qPCR was done on RNA extracted from HCT-15 and
HCT-116 parental cells, and from the same cells treated with siRNA
against CTCF for 72 hours. CTCF downregulation was confirmed and
BORIS upregulation was observed in both cell lines by qRT-PCR. The
relative expression levels of CTCF and BORIS isoforms was determined
by the comparative Ct method and normalized to control siRNA. (E)
Activation of p53 in H1299 lung cancer cell line results in the
suppression of all BORIS subfamilies. qPCR on RNA extracted from
parental H1299 and from H1299 with exogenously dox-induced p53
wild type shows upregulation of p53 and downregulation of BORIS
isoforms. Data were analyzed as in (C) and normalized to the expression
levels of p53, CTCF and BORIS subfamily expression in the H1299
parental cell line.
doi:10.1371/journal.pone.0013872.g009
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would parallel development in humans.
BORIS isoforms may have unique functions in ovaries
It has been reported that, in addition to testis, BORIS isoform B0
is expressed in human oocytes but not in adult ovaries [22]. This is
consistent with our results demonstrating that, among 13 fetal
tissues tested, only ovary was strongly positive for all six BORIS
subfamilies, but with varying levels of expression. The inability to
detect strong BORIS isoform expression in adult ovaries is likely
due to the fact that the contribution of oocyte to total ovarian
RNA diminishes with age. We presume that the strength of BORIS
isoform expression in fetal ovary can be attributed to oocytes-
specific transcripts. In this regard, BORIS isoforms are likely to
have some functions in oocytes, as early embryos rapidly become
BORIS-free [9].
A significant observation from the present work is that the
ovary-specific pattern of BORIS isoform expression is distinct from
that of adult testis (Fig. 4A,B). This may be due to the fact that
germline development in males is dramatically different from that
in females. With respect to meiosis, however, adult testis and fetal
ovaries are approximately at the same stage of maturation. Thus,
the differential expression of BORIS isoforms in fetal ovaries and
adult testis may suggest that isoforms are both functional and
specialized in these two germlines.
BORIS isoforms are aberrantly activated in a wide range
of cancers
One of the common characteristics of germ cell development
and cancer progression is the expression of CTAs, including
BORIS (catalogue number CT27) [26]. Studies from our
laboratory and others provide evidence that BORIS is aberrantly
activated in cancer cells of diverse origins [2,6,7,8,25,27,32,33].
The aberrantly activated BORIS isoproteins may play the role of a
‘‘mutant CTCF’’ in cancers, possibly through the competition of
BORIS with CTCF. These features prompted consideration of
BORIS as both a diagnostic biomarker in breast cancer [33] and as
a target for anti-cancer immunotherapy [24,36]. Furthermore,
BORIS is included in the priority-ranked list of cancer vaccine
target antigens [37].
Proteins encoded by BORIS isoforms can be considered as
CTAs, based on their expression in spermatocytes and upregula-
tion in a wide range of cancers (Fig. 4 and Fig. 5). Using qPCR, we
showed that all six BORIS subfamilies were expressed in 70% of
the NCI-60 cancer cell lines although most lines had fewer than
1500 total BORIS transcripts per 50 ng RNA. This level of
expression represents less than one transcript per cell, although
this could be an underestimate due to limitations in primer
selection for isoform detection (Fig. 2). The low levels of expression
determined here are in agreement with prior studies of cancer
tissues and cell lines, which showed that expression of the BORIS
B0 isoform was dependent on tumor stage, metastatic status and
type of cancer [8,25,27]. Similar features have been documented
for many other CTAs that showed restricted expression in a small
fraction of the tumor cell pool [26,38,39]. Elevated expression of
CTAs has been shown to characterize subpopulations of cells from
melanomas and gliomas [38,39]. Expression of BORIS in cancer
may therefore be limited to a subset of cells or to a particular stage
in tumor development. Further work on BORIS isoform expression
in cancer cell lines and primary tumors is needed to verify this
suggestion.
Results of the present work indicate that not only all BORIS
promoters but also the alternative splicing within the BORIS locus
are abnormally activated in cancers. The expression of individual
subfamilies differs between normal and cancer cells since neither
the pattern 1 nor pattern 2 of isoform expression in the NCI-60
panel resembled the expression profiles of adult testis or fetal
ovaries (Fig. 4 and Fig. 5). Aberrant promoter demethylation
possibly contributes to BORIS activation in cancer cells, as
indicated by the emergence of pattern 1, described in Figure 5B,
with a marked predominance of sf1 isoform expression. Indeed,
complete demethylation of promoter B correlated with the highest
levels of BORIS B0 isoform expression among NCI-60 cancer cell
lines [16]. Furthermore, while the profile of BORIS isoform
expression in parental HCT-116 cells matched pattern 2 of BORIS
isoforms expression in cancers with sf1-4 and sf6 are expressed at
about equal levels (Fig. 5C), the double KO cells resembled the
first pattern (Fig. 9B). As DNA methylation in double KO HCT-
116 cells was reduced by 95% compared to wild type, the pattern
1o fBORIS isoform expression is likely associated with extensive
hypomethylation of the CpG island in BORIS promoter [16].
Apart from CpG methylation, BORIS isoform expression is
decreased in response to p53 activation (Fig. 9E). This highlights
the potential importance of BORIS isoform expression as a
component of oncogenic cell transformation and agrees with our
earlier study on BORIS promoters showing negative regulation by
p53 [16].
DNA binding and transcriptional properties of BORIS
isoforms compared to CTCF: similarities and distinctions
There are two possible scenarios for BORIS competition with
CTCF when both genes are expressed in the same cell. First,
BORIS and CTCF may directly regulate expression of each other.
Indeed, we previously showed that there are CTCF binding sites
in all three BORIS promoters and that BORIS expression is
induced in response to downregulation of CTCF [8,16]. Further-
more, genome-wide ChIP studies indicated that there are multiple
sites inside BORIS exons and introns that are occupied by CTCF
[40], indicating possible additional levels of regulation. Second,
CTCF and BORIS compete for binding to sites in regulatory
elements of other genes [8,41].
The transcriptional effects of CTCF downregulation on its target
genes, all reported to have CTCF sites within their promoters, were
ascribed to either direct or downstream effects of reduced CTCF
occupancy at specific sites [30,31,42]. Our results showed that
downregulation of CTCF can lead to the increased expression of
multiple BORIS isoforms (Fig. 9C,D), indicating that competitive
BORIS binding is another possible contribution to CTCF
downregulation.
Characterizing BORIS isoform-specific functions and activities
that overlap with those of CTCF in vivo is a daunting task.
Nonetheless, characterization of the DNA binding specificities of
BORIS isoforms is a first essential step. All 17 BORIS isoproteins
contain a ZF DNA binding domain that can mediate recognition
of specific DNA targets. CTCF binds DNA with a wide range of
sequence specificities [1] making it uniquely multifunctional [5].
The differing number and composition of ZFs in BORIS
isoproteins may well expand the established multifunctionality of
the 11 ZF domain. Nevertheless, our studies showed that BORIS
isoproteins bind DNA in a fashion that is generally similar to that
of CTCF, at least for the two sites studied here. This similarity is
likely to be based on the high degree of identity (74%) between the
ZF regions of the two proteins and the conservation of the major
DNA recognition residues at the positions minus one, two, three
and six within each ZF [6]. Furthermore, the ZF domains of
BORIS isoproteins are both sufficient and necessary for DNA
binding (data not shown). In addition to the utilization of various
sets of ZFs to bind different sites, as was demonstrated for CTCF
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numbers and composition of ZFs. For example, binding of BORIS
isoproteins to the H19 ICR required at least nine ZFs (Fig. 7A),
whereas only five ZFs were required for binding the CST promoter
probe (Fig. 8B,C). Like CTCF, the efficiency of BORIS isoprotein
binding to DNA in vitro correlates with the number of ZFs in the
DNA-binding domain [43], while the ZF flanking domains of the
isoproteins likely contribute to complex ‘‘architecture’’. For
example, the five ZFs isoproteins C4 and C7 bound CST probes
more weakly than isoproteins with more ZFs (Fig. 8B,C). The
effects of amino-terminal truncations were also comparable for
BORIS isoproteins and CTCF (Fig. 7 and Fig. 8). BORIS
isoproteins with a long N-258 terminus produced equally high
band-shifts with different DNA targets, essentially regardless of
other protein domains. The truncation of N258 in isoproteins B2,
B3, B4 and B5 had no impact on DNA binding per se, but resulted
in a dramatic increase in EMSA complex migration (Fig. 7 and
Fig. 8). This effect is similar to that of the deletion of the amino-
terminus of CTCF [44], despite the fact that the amino-terminal
domains of CTCF and BORIS have less than 10% sequence
homology.
CTCF is recognized as a major regulator of epigenetic pathways
in mammals [5] while the evidence of BORIS involvement in
imprinting and other epigenetic phenomena remains fairly limited
[10]. Here we showed that binding of BORIS isoproteins to H19/
IGF2 ICR DNA is sensitive to methylation (Fig. 7B) as was
previously demonstrated for CTCF [13]. These data are in
agreement with a recently published study [45] but contrast with
findings described in another publication [29]. In general,
methylation sensitive CTCF binding sites, when binding BORIS
isoproteins, do so also in a methylation-sensitive manner.
In spite of the described similarities between BORIS isoproteins
and CTCF, their biology in vivo suggests the existence of non-
overlapping functions. Functional specialization of BORIS
isoforms could be generated by interactions with alternative
partner proteins, and by novel DNA binding activities of
isoproteins that do not correspond to CTCF-recognized sites. In
BORIS isoproteins, sequence divergence between the ZF
domains, differing numbers and utilization of ZFs, and the
absence of the CTCF AT hook motif may account for such
differences [6]. We also demonstrated that not every DNA target
exhibited equivalent binding of CTCF and BORIS. For example,
CTCF binding to the CST probe was weaker than for BORIS
isoproteins under the same EMSA conditions (Fig. 8B,C). This
could illustrate the potential for BORIS isoproteins, despite their
lower abundance, to compete with CTCF for site occupancies
genome wide.
We recently reported BORIS functions as a transcription factor
to regulate a subset of genes in germ cells [8,9]. In this case,
BORIS functions in gene expression could not be compensated by
CTCF in BORIS KO mice [9]. EMSA showed that BORIS
isoproteins could bind a probe from the testis-specific promoter of
CST (Fig. 8B,C). Furthermore, isoproteins having the long N258
terminus with at least the first five ZFs could activate this promoter
in transient luciferase assays (Fig. 8D). The isoproteins lacking the
N258 terminus failed to activate reporter transcription, despite
being able to bind the CST probe in EMSA (Fig. 8). Thus, the
N258 terminus apparently harbors an activator domain. Inciden-
tally, the N267 terminus of CTCF was previously implicated in
transcriptional activation of APP promoter [43] even though there
is only a low degree of similarity between the amino-termini of
CTCF and BORIS N258 isoproteins. The correlation between the
N258 contribution to the size of the BORIS isoform complexes in
EMSA and its transcriptional activity suggests that changed
protein conformation and/or stoichiometry in BORIS/DNA
complexes contribute to its transcription activation potential.
Our data thus support the view that BORIS isoproteins can both
partially replace and interfere with CTCF in germline develop-
ment and cancers, in manners dependent on the nature of the
specific target site. The fact that BORIS has multiple isoproteins
may enhance the range of potential binding sites over the CTCF
target sites. Future studies analyzing the occupancy of CTCF
target sites by BORIS isoproteins and expression profiles of
potential targets in germ cells and cancers will be needed to
decipher the functions of BORIS isoproteins.
The potential functional significance of multiple BORIS
isoforms in the germline
While specialized functions of individual BORIS isoproteins
remains to be documented, it is likely that expression of multiple
isoforms from the human BORIS locus is biologically important.
This is indicated first, by the differing isoform repertoires in male
and female germ cells (Fig. 4) and the distinct patterns of
expression in different cancer cell lines (Fig. 5B,C). Second,
BORIS isoforms are evolutionarily conserved in primates. It is
generally accepted that alternative splicing, if conserved among
different species, is likely to reflect biologically important variations
[35]. In this report, we describe the high conservation of splicing
sites and alternative coding sequences in BORIS loci in primates,
including Homo sapiens, Pan troglodytes and Macaque mullata (Fig. 3).
Third, an alternative ZF is found in isoform C6 (Fig. 2B), and such
precise ‘‘protein engineering’’ is unlikely to be accidental. Even
though this isoform does not bind the probes we tested, it probably
has a specific set of targets in vivo. Another ‘‘naturally engineered’’
isoform, A3, while binding weakly to the CST probe (Fig. 8B,C),
has shown some transcriptional activation potential on other
targets in vivo (to be published elsewhere). Finally, the different
transcriptional activity of individual isoproteins supports the idea
of biologically relevant functional specialization.
What could be the functional advantages of expressing multiple
BORIS isoproteins in the germline? Spermatogenesis and
oogenesis are multistage processes, involving tightly controlled
cell-specific activation and/or repression of a wide spectrum of
genes at every stage of germ cell development. The sheer
complexity and tight regulation of this multistep process
apparently requires engagement of active alternative splicing for
multiple genes, especially transcriptional factors in germline. One
prominent example is CREM (cAMP Responsive Element
Modulator) that regulates expression of many male fertility genes
and is expressed through all stages of spermatogenesis. The CREM
locus produces multiple isoforms with either activation or
repressive activities depending on exon configuration in the
alternative transcripts [46]. The fact that some BORIS isoproteins
can bind the CST promoter and activate transcription while others
can bind the same promoter but do not display transcriptional
activity (Fig. 8) suggests that BORIS isoforms, similarly to CREM,
can perform opposing functions with the same DNA target.
Taken together, the data in this study demonstrate that the
BORIS gene is much more complex than initially appreciated. Our
results demonstrate that multiple isoforms expressed from human
BORIS gene encode isoproteins that can bind DNA and function
as transcription factors. These proteins have the potential to
compete with CTCF for binding to DNA and can possibly
modulate or block CTCF functions at these targets in vivo.
Although our data have significantly enhanced the understanding
of BORIS complexity, additional studies are needed to ascertain
the significance and the functional role of each BORIS isoform.
Ethics Statement: N/A
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Cell lines and treatment
Cancer cell lines or primary normal cells were either described
previously [8,16] or were obtained from the ATCC (Manassas,
VA) and were grown as suggested by distributors. The NCI-60
cancer cell line panel was obtained from the National Cancer
Institute. The NCI-60 cell lines were cultured in RPMI with 5%
FBS and antibiotics. Wild type, DNMT12/2, DNMT3b2/2
and DKO (DNMT12/2,3 b 2/2) HCT116 colorectal cancer
cell lines were provided by Dr. Bert Vogelstein (Johns Hopkins
Medical Center, Baltimore MD) and were cultured in McCoy’s 5A
medium supplemented with 10% FBS and antibiotics. The H1299
lung cancer cell line with a wild type, stably-transfected,
doxycycline-inducible p53 expression vector, a gift from Dr. Peter
M. Chumakov (Lerner Research Institute, Cleveland, OH), was
cultured in DMEM with 10% FBS. HCT-15 and HCT-16 colon
cancer cell lines from the NCI-60 panel were treated for 72 h with
freshly prepared 5 mM 5-aza-29-deoxycytidine (5-azadC) (Sigma-
Aldrich, St. Louis, MO) and/or with 3 mM histone deacetylase
inhibitor, Trichostatin A (TSA) (Sigma), dissolved in ethanol.
RNA ligase-mediated rapid amplification of cDNA ends
(RLM-RACE)
To isolate full length BORIS transcripts, we used the 39 RLM-
RACE approach (Fig. 1C). Full-length RLM-RACE libraries were
generated using total RNA from adult testis and K562 cells, as
suggested by the manufacturer manual (Invitrogen, Catalog
number: L1500-01). As promoter utilization may have some
influence on splicing regulation, the three forward primers - A, B,
and C – were designed to amplify mRNAs expressed from the
respective promoters (Fig. 1C, Table S1). As a reverse primer we
used 39 GeneRacer oligo attached to a polyA tail during first-
strand cDNA synthesis. To increase the yield and specificity of
RACE-PCR products, a second nested round of PCR amplifica-
tion was performed using 1 ml of the first round reaction. PCR
with Platinum Taq polymerase (Invitrogen) was done for 40 cycles
of 30 s at 95uC, 30 s at 60uC and 4 min at 72uC with a final
extension at 72uC for 7 min. Amplified products were separated
by electrophoresis in 1% agarose gels, excised, purified by Gel
Extraction Kit (QIAGEN Inc, Chatsworth, CA), cloned into the
pCRH2.1-TOPOH vector (Invitrogen), and sequenced using LI-
COR sequencing system (LI-COR Biosciences Inc., Lincoln, NE).
RNA and cDNA samples used in RT-PCR assay
25 mg of total RNA from 13 adult and 11 fetal tissue samples
were from Stratagene, (La Jolla, CA). FastClone RACE-Ready
cDNA from fetal testis and fetal ovary was from Spring Bioscience
(Fremont, CA). Another source of fetal ovary (28 weeks old) was
obtained from BioChain (Hayward, CA). Five different sources of
total RNA from adult testis were analyzed for BORIS isoform
expression: 1) the lowest level of BORIS transcripts (10-fold lower
level of BORIS isoforms expression, compared to four followed
samples) was detected in testis RNA obtained from OriGene
Technologies (Rockville, MD, Catalog Number: HT-1011). 2)
testis RNA from 72 year old male (Stratagene). 3, 4, 5) Total RNA
was extracted by Trizol from normal adult testis samples from 23,
21 and 29 year old males (NDRI, Philadelphia, PA).
CTCF knock down by RNAi
HCT-15 and HCT-116 cell lines were transfected with 5 mM
of human CTCF ON-TARGETplus SMART pool siRNA
(Dharmacon Inc., Lafayette, CO). A siCONTROL Non-Target-
ing siRNA (Dharmacon Inc.) was used as negative control in all
siRNA experiments. Cells were harvested after 48 or 72 h for
western and quantitative RNA expression analysis.
Standard RT-PCR and Quantitative Real-Time RT- PCR
(qPCR)
Total RNA was incubated at 70 C for 10 min, cooled on ice,
and then cDNA was synthesized using a ThermoScript reverse
transcription kit (Invitrogen), using an oligo(dT)18 primer. The
reverse transcription reaction was performed as follows: 42uC for
60 min, 85uC for 10 min and 4uC for 10 min. 2 mL of cDNA was
amplified in a 50 mL volume containing Platinum Taq DNA
polymerase (Invitrogen). The reaction mix was incubated for 35
cycles (95 C for 30 s, 60 C for 30 s, 72 C for 1–3 min). The
primers used in RT-PCR are shown in Table S1. To analyze the
expression patterns of BORIS isoforms in normal and cancer cells,
BORIS isoforms were divided into six subfamilies, sf1 to sf6, based
on their unique 39 sequences (Fig. 2A). The Taqman probe sf1 was
designed against sequences between exon 9 and 10 of the BORIS
B0 and detects BORIS isoforms B0, B1, A1, A2, A3, and C1 (Fig. 2,
File S1, Table S3). The absolute quantification approach was
applied to estimate the actual number of BORIS transcripts
detected by sf1 per 50 ng of total RNA. BORIS B1 contains the
unique splice site that was used to design the sf5 probe and the
total number of B1 transcripts was subtracted from the total
number of transcripts detected by the sf1 probe. The Taqman
probe sf2 detects at least two BORIS isoforms, A4 and C2, that
produce the same protein but are expressed from two alternative
promoters, A and C, respectively. The Taqman sf3 probe detects
five isoforms: A5, A6 B4, B5, and C6. The Taqman probe sf4 was
designed to detect at least six BORIS isoforms: C3, B2, B3, C4, C5,
and C8. The B1 isoform has a unique C-terminus and 39 UTR
that were used to design the sf5 probe. The sf6 probe detects four
BORIS isoforms: B6, B7, C7, and C9.
For absolute and relative quantification of BORIS alternative
transcripts as well as CTCF, GAPDH and p53 expression, qRT-
PCR was done using the ABI Prism 7900 Sequence Detection
System (Applied Biosystems, Foster City, CA). 5 ml of each cDNA
corresponding to 50 ng of total RNA was amplified in a total
volume of 11 ml using the universal PCR Master mix (Applied
Biosystems, Foster City, CA) with 250 nM of primers and 200 nM
Tagman probe. Amplification conditions were: 50uC for 2 min,
95uC for 10 min, followed by 45 cycles of 95uC for 15 s and 60uC
for 1 min. All reactions were prepared in triplicate, and at least
three independent runs were performed for each sample. Primers
to analyze BORIS alternative transcripts were selected using
Primer Express Software (Applied Biosystems). The efficiencies of
all PCRs were above 95%. All specific primers and Taqman
probes are listed in Table S2. Expression of GAPDH was used as
an endogenous control. The relative quantification of gene
expression was done using a comparative 2-ddCt method (Applied
Biosystems). The absolute quantification of gene expression was as
described previously [16].
Vector construction and transfections
The open reading frames of 17 alternative BORIS transcripts,
encoding 17 BORIS isoproteins, were initially amplified by nested
RT-PCR with cDNA from K562 cell line and/or from normal
testis using primers shown in Table S1. The amplification
introduced a HA-Tag at the N-terminus of each BORIS isoform
as well as 59-NcoI and EcoRI restriction sites and 39-NotI and NheI
sites, to facilitate subsequent cloning into different vectors. PCR
products after the second round of amplification were cloned into
the pCR2.1-TOPO vector (Invitrogen) and sequenced. The
pCITE4a vectors (Novagen, Madison, WI) for 17 BORIS
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were generated by re-cloning EcoRI- and NotI- fragments from
TOPO vectors into pCITE4a vector cleaved with the same
enzymes. The vectors used for luciferase co-transfection experi-
ments were made by cloning the same fragments into the pCI
vector (Promega, Madison, WI). The BORIS-DsRed constructs
that were used in transient transfections to detect the localization
of BORIS isoproteins were generated by making the EcoRI- and
NotI- ORF fragments blunt-ended with Klenow enzyme (New
England Biolabs, Inc., Beverly, MA) and cloning them into the
pDsRed-Monomer-Hyg-C1 vector (Clontech Laboratories Inc.,
Mountain View, CA) cleaved with XmaI followed by Klenow
enzyme treatment. The luciferase reporter constructs contained a
luciferase gene driven by either a 359 bp wild-type or mutant
testis-specific CST promoter based on the pGL3-basic vector
(Promega), previously described in detail [9]. All transfections were
done with the jetPEI Cationic Polymer Transfection reagent
(PolyPlus-transfection, Illkirch, France) according to the manufac-
turer’s instructions, except HEK293T cells, which were transfect-
ed using TransIt transfection agent according to manufacturer’s
protocol (Mirus Bio, Madison, WI). All individual transfections
used in quantitative assays were performed at least three times.
Transiently transfected cells were harvested either 48 or 72 h after
transfection. For stable transfection, an antibiotic was added 3
days post transfection and colonies were selected for three weeks.
Electrophoretic mobility shift assay (EMSA)
Fragments containing mouse and human testis-specific CST
promoters or the H19-IGF2 sixth CTCF target site were
synthesized by PCR with primers shown in Table S1. EMSA
was performed as previously described [4]. Briefly, PCR fragments
were labeled using
32P-c-ATP with T4 polynucleotide kinase (New
England Biolabs). Protein–DNA complexes were incubated for
90 min at room temperature in binding buffer containing 25 mM
Tris pH 7.4, 0.1 mM ZnSO4, 5 mM MgCl2, 5% Nonidet P-40 in
PBS, 0.25 mM Mercaptoethanol, 10% glycerol and 0.5 mg of poly
dI-dC. Protein–DNA complexes were separated from the
unbound probe using 5% native polyacrylamide gels (PAAG).
Full-length CTCF and 17 BORIS isoforms that were cloned into
the pCITE4a vector were translated in vitro using a TnT kit
(Promega). The equivalent yield of proteins was confirmed by
35S
methionine incorporation with subsequent PAAG separation and
quantification.
Luciferase Assay
For luciferase assays, 5610
5 HEK293T cells were grown in 6-
well plates and co-transfected with 2 mg of plasmid DNA using
TransIt transfection agent (Mirus Bio). Each transfection included
0.8 mg of pCI plasmid containing the mouse Ctcf ORF or mouse
Boris or human BORIS isoforms, 1 mg of pGL-3 containing 359 bp
of wild-type or mutant mouse CST promoter [9], and 0.2 mgo f
pRL-TK renilla luciferase vector. After 48 hours, cells were lysed
in 200 ml passive lysis buffer (Promega) and analyzed in a
Microbeta luminescence counter 1450 (Perkin Elmer, Boston,
MA) using a dual luciferase reporter assay kit (Promega). All
luciferase activities were normalized for transfection efficiency by
measuring the Renilla luciferase activity of the co-transfected pRL-
TK vector.
Northern and western blotting
Northern blotting was done using NorthernMax formaldehyde-
based system (Ambion Inc., Austin, TX) according to the
manufacturer’s recommendations. Briefly, 30 mg total RNA was
loaded per lane, separated in agarose gels, transferred to a
positively charged nylon membrane (BrightStar-Plus, Ambion
Inc.), cross linked by UV, and hybridized with labeled probes at
42uC. The six probes were labeled internally using Strip-EZ PCR
Kit (Ambion Inc.) according to the manufacturer’s recommenda-
tions (Primers shown in Table S1). For western blotting total cell
lysates were prepared in SDS-lysis buffer (0.1M Tris/HCl pH6.8,
7M Urea, 10% mercaptoethanol, 4% SDS & phenol red dye). The
lysis buffer was added at a ratio of 20 ml per 1610
5 cells. Cell
lysates were heated at 95uC for 5 minutes, centrifuged at 12000 g
for 5 sec., loaded onto SDS gels, transferred to PVDF membrane
(Invitrogen), probed with rat monoclonal Anti-HA antibody
(1:2000) (Roche, Indianapolis, IN, Catalog number 13551000),
and then probed with peroxidase-conjugated rabbit anti-rat IgG
(1:5000) (Abcam, Cambridge, MA). Proteins were visualized using
enhanced chemiluminescence (Pierce, Rockford, IL).
RNase Protection Assay
cDNAs representing different subfamilies and BORIS C6
isoform were cloned by RT-PCR using total testis RNA as
template. The sequence of primers could be found in Table S1.
The PCR bands were extracted from an agarose gel, cloned into
pCRII-TOPO vector by TA-cloning (Invitrogen), and sequenced
to verify the insertion and antisense orientation. The vector was
linearized by BamHI digestion, and riboprobe was synthesized
from T7 promoter in the presence of 50 mCi of [a-32P] CTP
(3000 Ci/mmol) by MAXIscript Kit according to the manufac-
turer’s recommendations (Ambion Inc.). The DNA template was
removed by incubation with RNase-free DNase (1 U/mg of DNA)
and the RNA probes were gel purified to isolate only full-length
RNA transcripts. 20 mg of total RNA from kidney, testis or the
K562 cell line was incubated with riboprobe (7610
5 cpm/sample)
in 80% formamide, 40 mM PIPES (pH 6.4), 0.4 M NaCl, and
1 mM EDTA overnight at 54uC. RNase digestion and precipita-
tion was performed with RPA III Kit according to the
manufacturer’s recommendations (Ambion Inc.). RNase protected
fragments were resolved on 5% polyacrylamide/8 M urea gel in
the presence of size markers to aid in the identification of bands.
Immunofluorescence and fluorescent in situ
hybridization (FISH)
4610
4 HEK293T cells were plated in 8-well chambered
coverglass (Nalge-Nunc, Naperville, IL) 24 h before transfection.
dsRFP-fusion BORIS transcripts (200 ng) were introduced into
HEK293T cells using TransIT Transfection Reagent (Mirus Bio).
After 24–48 h of transfection, cells were fixed in 4% formaldehyde
in PBS for 30 min, permeabilized with 0.5% Triton-X100, and
stained with 49, 6-diamidino-2-phenylindole (DAPI, Vector
Laboratories, Inc., Burlingame, CA). RFP fluorescence patterns
were observed by fluorescent microscope (Axioscop 2 plus, Zeiss,
Germany). For FISH assays, the probes for six BORIS subfamilies
(primers are shown in Table S1) were labeled with digoxygenin-
11-dUTP (Roche, Indianapolis, IN) by PCR and individually
hybridized to formaldehyde-fixed adult human testis as previously
described [47]. The slides were incubated with anti-DIG
antibodies overnight and then visualized with rhodamine-conju-
gated secondary antibody. For identification of spermatogonia and
spermatocytes, the frozen testis slides were fixed and incubated
with anti-SCP3 (NB300-231, Novus Biologicals, Inc., Littleton,
CO; 1:300 in 3% BSA) and E-cadherin (ab1416, Abcam,
Cambridge, MA; 1:50 in 3% BSA) for 2 hours, followed by
incubation with Alexa Fluor 488/546-conjugated (Invitrogen,
Carlsbad CA; 1:500 in PBS) secondary antibody for 1 h. For
staining of DNA, DAPI was used.
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File S1 The full-length nucleotide and deduced amino acid
sequence of the individual BORIS isoforms.
Found at: doi:10.1371/journal.pone.0013872.s001 (0.40 MB
RTF)
File S2 BORIS isoforms B0, C2, A5, C3, B1 and C7/C9 are the
dominant representatives of the six BORIS subfamilies.
Found at: doi:10.1371/journal.pone.0013872.s002 (0.07 MB
RTF)
Figure S1 The 23 alternatively spliced RNAs are predicted 17
protein isoforms with three alternative N-termini and eleven
alternative C-termini. Unique alternative C-termini labeled by
different colors.
Found at: doi:10.1371/journal.pone.0013872.s003 (0.70 MB TIF)
Figure S2 Alignment of alternative C-terminus C97, present in
BORIS C3, B2, and B3 isoforms, demonstrated a similarity from
52% to 72% with more than 100 human proteins, some of them
are involved in transcription or translation processes. The proteins
sharing homology with C97 include: transmembrane protein 50B
(TMEM50B) (56%), general transcription factor IIH (GTF2H1)
(61% identity), seven transmembrane helix receptor (GPR110)
(58%), INO80 complex homolog 1 (INO80) (59%), putative
calcium-sensing receptor-like 1 (64%), syntaxin 8 (STX8) (72%),
vitamin K epoxide reductase complex (VCORC1) (65%),
topoisomerase II alpha-4 (TOP2A) (56%), elongation protein 4
homolog (ELP4) (62%), SSU72 RNA polymerase II CTD
phosphatase homolog (SSU72) (58%), sarcosine dehydrogenase
(SARDH) (53%), translation initiation factor eIF-2B subunit
alpha/beta/delta-like protein (MRI1) (60%) and many more.
Found at: doi:10.1371/journal.pone.0013872.s004 (3.88 MB TIF)
Figure S3 All BORIS isoproteins are located in nuclei.
HEK293T cells were transiently transfected with either dsRRED
empty vector (EV-dsRED) or with BORIS isoforms and CTCF
fused to dsRRED or GFP at N-terminus, respectively. RFP and
GFP fluorescence were analyzed by microscopy. dsRED protein
(Empty Vector (EV)-dsRED) was served as a marker for
cytoplasmic location. Cells were also stained with DAPI to
visualize nuclear DNA. At the bottom of right column the high
magnification image of BORIS B0 transfected cells are shown to
demonstrate the punctual pattern of BORIS nuclear location.
Found at: doi:10.1371/journal.pone.0013872.s005 (2.85 MB TIF)
Figure S4 BORIS isoforms subfamilies are comprised by
distinctly expressed individual isoforms. (A). A schematic illustra-
tion of BORIS promoters and exons usage for the expression of 23
mRNA isoforms. The rectangular boxes at the bottom denote the
locations and sizes of probes that were used for Northern blotting.
Arrows correspond to primers that were used in RT-PCR assays.
The colors of boxes and arrows correspond to the unique coding
alternative sequences as in Figure 2. (B). Northern blotting analysis
of BORIS isoforms expression in the K562 cell line, adult testis and
kidney. The top 6 gels correspond to six internally
32P-labeled
probes for 6 BORIS subfamilies. The bottom gels are loading
controls based on ribosomal RNA. The six labeled probes were
designed to detect all isoforms of 6 BORIS subfamilies. Sequences
of primers used to generate Northern probes are shown in Table
S1. The dominant transcripts are indicated by arrows with a
corresponding name of BORIS isoform. The sizes of RNA
transcripts are shown on the right side of the membrane. (C).
RT-PCR assay to simultaneously detect multiple isoforms within
six BORIS subfamilies by using one or two set of primers. Agarose
gels are shown for every BORIS subfamily (BORIS _sf1-sf6). The
PCR products were generated from adult testis and the K562
cDNAs by nested RT-PCR. H2O and RNA extracted from heart
were used as negative controls for BORIS expression. The primers
that were used to amplify single or multiple transcripts within one
subfamily are named accordingly to their mapping to BORIS
exons and shown at the bottom of each gel. These primers are also
shown in panel A; the sequence of primers is shown in Table S1.
PCR products with the size of expected alternative transcripts are
indicated by arrows with the name of corresponding isoform.
Subpanel 1). To simultaneously amplify BORIS B0 and A3
transcripts within sf1, we used the forward primer from exon 5
(Ex5) and the reverse primer from exon 10 (Ex10). Subpanel 2).
For BORIS sf2 two pair of primers were used to analyze the
expression of A4 and C2 isoforms. RT-PCR with forward primers
from promoter A (Exa) or C (Ex1c) and reverse primer from the
unique sequence of alternative exon 4a (Ex4a) yielded much
stronger signal on agarose gels with a forward primer going from
promoter C, then from promoter A, suggesting C2 as a main
isoform in sf2. Subpanel 3). To distinguish expression of A6, A5
and B5 isoforms within sf3, two pairs of primers with the same
reverse primer from alternative exon 9a (Ex9a) were used in RT-
PCR. The forward primers from exon 4 (Ex4) or from exon 8
(Ex8) amplified three different PCR products corresponding to
three BORIS alternative forms, indicated by arrows. Subpanel 4).
To compare C3 isoform expression to C4 and C5 within sf4, the
forward primer from exon3 (Ex3) and the reverse primer from the
alternative exon 10b (Ex10b) were used. The forward and reverse
primers from non-coding exon b (Ex1b) and exon 3 (Ex3),
respectively, generated three PCR products corresponding to
multiple BORIS isoforms with alternative splice sites from exon b
to exon 1 (BORIS B0), exon 2 (B3/B4) and exon 3 (B2/B5/B6/B7).
The splice site from exon b to exon1 is more dominant than the
splice sites from exon b to exon 2 and 3. Subpanel 5). B1 isoform
was amplified as single form by primers from exon 9 (Ex9) and
exon 10a (Ex10a). Subpanel 6). To compare C7/C9 and B6/B7
isoforms expression, RT- PCR was done with two forward primers
from exon b (Exb) and exon 1c (Ex1c), and with the reverse primer
from alternative exon 5a (Ex5a). The primer from the promoter C
(Ex1c, C7/C9) yielded more abundant PCR product then the
forward primer from promoter B (Exb). (D) and (E). Absolute
quantification of individual BORIS isoforms within sf3 and sf4.
The total number of transcripts, detected by both Tagman probes
BORIS_sf3 and BORIS_sf4, in the K562 or adult testis was set as
100%. The contribution of single isoform to the total amount of
subfamilies’ transcripts was calculated by absolute quantification
with the series of Taqman probes either to unique sequences or to
unique alternative splice sites. The sequence of primers and
Tagman probes are shown in Table S2. (D) The sf3 Taqman
probe detects 5 BORIS isoforms - A5, A6, B4, B5, and C6 (Fig. 2B).
Total combined amount of these transcripts was set at 100%, and
the amount of single transcripts for 4 out of 5 sf3 isoforms was
calculated by absolute qRT-PCR using Taqman probes designed
to quantify isoforms A6 (Ex8-Ex9a1), B5 (Ex8- Ex9a2), B4 (Exb-
Ex2), and C6 (Ex4-Ex8). Together, these isoforms represent less
than 31% of the total amount of BORIS transcripts detected by
the sf3 probe. The percent of main BORIS A5 isoform contributing
to the total amount of all isoforms detecting by the sf3 Tagman
probe is shown on the graph. BORIS A5 and BORIS C3 were found
to be the main isoforms in sf3 and sf4, respectively. (E) The sf4
Taqman probe detects 6 BORIS isoforms - C3, B2, B3,C4, C5, and
C8 (Fig. 2A). Total combined amount of these transcripts was set
at 100%, and the amount of single transcripts for 5 out of 6 sf4
isoforms was calculated by absolute qRT-PCR using Taqman
probes designed to quantify isoforms B2 (Exb-Ex3), B3 (Exb- Ex2),
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these isoforms represent less than 21% of the total amount of
BORIS transcripts detected by the sf4 probe. The percent of main
BORIS C3 isoform contributing to the total amount of all isoforms
detecting by the sf4 Tagman probe is shown on the graph. (F). The
schematic illustration of 6 dominant BORIS isoforms showing their
belonging to 6 BORIS subfamilies. (G). Summary table of the 6
dominant BORIS isoforms representing the 6 subfamilies.
Found at: doi:10.1371/journal.pone.0013872.s006 (1.83 MB TIF)
Table S1 Table of primers used in RT-PCR and PCR assays.
Found at: doi:10.1371/journal.pone.0013872.s007 (0.11 MB
DOC)
Table S2 The primers and the Tagman probes used in qRT-
PCR.
Found at: doi:10.1371/journal.pone.0013872.s008 (0.04 MB
DOC)
Table S3 The 23 alternatively spliced BORIS mRNAs are
predicted 17 isoproteins. Table 3 summarizes the information
about BORIS alternative forms, including the size of alternative
transcripts in nucleotides, the size of isoproteins in kDA, the
calculated isoelectric point of each protein, the number of ZF per
isoform, the alternative N- and C-termini and the GenBank
accession number for each BORIS isoform.
Found at: doi:10.1371/journal.pone.0013872.s009 (0.05 MB
DOC)
Table S4 Exon-Intron Junctions of the BORIS gene. The major
spliceosome splices introns containing GU at the 59 splice site and
AG at the 39 splice site.
Found at: doi:10.1371/journal.pone.0013872.s010 (0.05 MB
DOC)
Table S5 Table of BORIS Expressed Sequence Tags (EST) in
Gene Bank.
Found at: doi:10.1371/journal.pone.0013872.s011 (0.03 MB
DOC)
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